Arcus Biosciences is a biopharmaceutical company dedicated to the development of best-in-class cancer therapies. With a focus on combining the expertise of scientists, physicians, and advisors, Arcus aims to bring effective cures for cancer. They prioritize the pursuit of cures for cancer and are committed to making a meaningful impact in this field.

Arcus Biosciences offers a range of products and services to achieve their goals. They have an extensive pipeline of discovery and clinical candidates, including therapies targeting TIGIT, adenosine pathway, PD-1, and HIF-2⍺. These candidates are being studied in clinical trials, investigator-sponsored programs, and expanded access programs.

Arcus differentiates itself through its strong discovery capabilities, producing innovative small molecules and antibodies designed to optimize combination therapies. They also prioritize accelerated development, guided by specific biologic mechanisms of cancer, to advance their therapies from Phase 1 studies to commercialization. Additionally, Arcus actively collaborates with the cancer community, facilitating global clinical trials and bringing new medicines to patients faster.

Join Arcus Biosciences in their mission to defeat cancer by exploring their latest press releases and announcements, participating in their clinical trials, and connecting with them. Together, let's combine efforts to cure cancer